Role of Warfarin Pharmacogenetic Testing in Clinical Practice

• Ansell J , HirshJ, HylekE et al.: Pharmacology and management of the vitamin K antagonists: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition).Chest133(Suppl. 6) , S160–S198 (2008).
   PubMed Web of Science ®Google Scholar
• Daly AK , KingBP: Pharmacogenetics of oral anticoagulants.Pharmacogenetics13(5) , 247–252 (2003).
   PubMedGoogle Scholar
• Hirsch J , DalenDE, AndersonD et al.: Oral anticoagulants.Chest119(Suppl. 1) , 8–21 (2001).
   PubMed Web of Science ®Google Scholar
• Jonas D , McLeodH: Genetic and clinical factors relating to warfarin dosing.Trends Pharmacol. Sci.30(7) , 375–386 (2009).
   PubMed Web of Science ®Google Scholar
• Gage BF , YanY, MilliganPE et al.: Clinical classification schemes for predicting hemorrhage: results from the National Registry of Atrial Fibrillation (NRAF).Am. Heart J.151(3) , 713–719 (2006).
   PubMed Web of Science ®Google Scholar
• Miners JO , BirkettDJ: Cytochrome P4502C9: an enzyme of major importance in human drug metabolism.Br. J. Clin. Pharmacol.45(6) , 525–538 (1998).
   PubMed Web of Science ®Google Scholar
• Li T , ChangCY, JinDY, LinPJ, KhvorovaA, StaffordDW: Identification of the gene for vitamin K epoxide reductase.Nature427(6974) , 541–544 (2004).
   PubMed Web of Science ®Google Scholar
• O‘Reilly RA , AggelerPM: Studies on coumadin anticoagulant drugs: initiation of warfarin therapy without a loading dose.Circulation38(1) , 169–177 (1968).
   PubMed Web of Science ®Google Scholar
• Yin T , MiyataT: Warfarin dose and the pharmacogenomics of CYP2C9 and VKORC1 – rationale and perspectives.Thromb. Res.120(1) , 1–10 (2007).
   PubMed Web of Science ®Google Scholar
• Connolly S , PogueJ, HartR et al.; Active Writing Group of the ACTIVE Investigators: Clopidogrel plus aspirin versus oral anticoagulation for atrial fibrillation in the Atrial fibrillation Clopidogrel Trial with Irbesartan for prevention of Vascular Events (ACTIVE W): a randomised controlled trial. Lancet367(9526) , 1903–1912 (2006).
   PubMed Web of Science ®Google Scholar
• Higashi MK , VeenstraDL, KondoLM et al.: Association between CYP2C9 genetic variants and anticoagulation-related outcomes during warfarin therapy.JAMA287(13) , 1690–1698 (2002).
   PubMed Web of Science ®Google Scholar
• Schwarz UI , RitchieMD, BradfordY et al.: Genetic determinants of response to warfarin during initial anticoagulation.N. Engl. J. Med.358(10) , 999–1008 (2008).
   PubMed Web of Science ®Google Scholar
• Gage BF , EbyCS: Pharmacogenetics and anticoagulant therapy.J. Thromb. Thrombolysis16(1–2) , 73–78 (2003).
   PubMed Web of Science ®Google Scholar
• Lindh JD , HolmL, AnderssonML, RaneA: Influence of CYP2C9 genotype on warfarin dose requirements – a systematic review and meta-analysis.Eur. J. Clin. Pharmacol.65(4) , 365–375 (2009).
   PubMed Web of Science ®Google Scholar
• Aithal GP , DayCP, KestevenPJ, DalyAK: Association of polymorphisms in the cytochrome P450 CYP2C9 with warfarin dose requirement and risk of bleeding complications.Lancet353(9154) , 717–719 (1999).
   PubMed Web of Science ®Google Scholar
• Goldstein JA , de Morais SM: Biochemistry and molecular biology of the human CYP2C subfamily. Pharmacogenetics4(6) , 285–299 (1994).
   PubMedGoogle Scholar
• D‘Andrea G , D‘AmbrosioR, MargaglioneM: Oral anticoagulants: pharmacogenetics Relationship between genetic and demonstrated genetic factors.Blood Rev.22(3) , 127–140 (2008).
   PubMed Web of Science ®Google Scholar
• Gage BF , MilliganPE: Pharmacology and pharmacogenetics of warfarin and other coumarins when used with supplements.Thromb. Res.117(1–2) , 55–59 (2005).
   PubMed Web of Science ®Google Scholar
• Wadelius M , ChenLY, LindhJD et al.: The largest prospective warfarin-treated cohort supports genetic forecasting.Blood113(4) , 784–792 (2009).
   PubMed Web of Science ®Google Scholar
• Ageno W , JohnsonJ, NowackiB, TurpieAG: A computer generated induction system for hospitalized patients starting on oral anticoagulant therapy.Thromb. Haemost.83(6) , 849–852 (2000).
   PubMed Web of Science ®Google Scholar
• Aquilante CL , LangaeeTY, LopezLM et al.: Influence of coagulation factor, vitamin K epoxide reductase complex subunit 1, and cytochrome P450 2C9 gene polymorphisms on warfarin dose requirements.Clin. Pharmacol. Ther.79 (4) , 291–302 (2006).
   PubMed Web of Science ®Google Scholar
• Carlquist JF , HorneBD, MuhlesteinJB et al.: Genotypes of the cytochrome p450 isoform, CYP2C9, and the vitamin K epoxide reductase complex subunit 1 conjointly determine stable warfarin dose: a prospective study.J. Thromb. Thrombolysis.22(3) , 191–197 (2006).
   PubMed Web of Science ®Google Scholar
• Bodin L , VerstuyftC, TregouetDA et al.: Cytochrome P450 2C9 (CYP2C9) and vitamin K epoxide reductase (VKORC1) genotypes as determinants of acenocoumarol sensitivity.Blood106(1) , 135–140 (2005).
   PubMed Web of Science ®Google Scholar
• Sconce EA , KhanTI, WynneHA et al.: The impact of CYP2C9 and VKORC1 genetic polymorphism and patient characteristics upon warfarin dose requirements: proposal for a new dosing regimen.Blood106(7) , 2329–2333 (2005).
   PubMed Web of Science ®Google Scholar
• Suttie JW : The biochemical basis of warfarin therapy.Adv. Exp. Med. Biol.214 , 3–16 (1987).
   PubMedGoogle Scholar
• Zimmerman A , MatschinerJT: Biochemical basis of hereditary resistance to warfarin in the rat.Biochem. Pharmacol.23(6) , 1033–1040 (1974).
   PubMed Web of Science ®Google Scholar
• D‘Andrea G , D‘AmbrosioRL, Di Perna P et al.: A polymorphism in the VKORC1 gene is associated with an interindividual variability in the dose-anticoagulant effect of warfarin. Blood105(2) , 645–649 (2005).
   PubMed Web of Science ®Google Scholar
• Rieder MJ , ReinerAP, GageBF et al.: Effect of VKORC1 haplotypes on transcriptional regulation and warfarin dose.N. Engl. J. Med.352(22) , 2285–2293 (2005).
   PubMed Web of Science ®Google Scholar
• Caldwell MD , AwadT, JohnsonJA et al.: CYP4F2 genetic variant alters required warfarin dose.Blood111(8) , 4106–4112 (2008).
   PubMed Web of Science ®Google Scholar
• Borgiani P , CiccacciC, ForteV et al.: CYP4F2 genetic variant (rs2108622) significantly contributes to warfarin dosing variability in the Italian population.Pharmacogenomics10(2) , 261–266 (2009).
   PubMed Web of Science ®Google Scholar
• Takeuchi F , McGinnisR, BourgeoisS et al.: A genome-wide association study confirms VKORC1, CYP2C9 and CYP4F2 as principal genetic determinants of warfarin dose.PLoS Genet.5(3) , E1000433 (2009).
   PubMed Web of Science ®Google Scholar
• Weibert RT , PalinkasLA: Differences in warfarin dose requirements between Asian and Caucasian patients.Clin Pharmacol.49 , 151 (1991).
   Google Scholar
• Lee CR , GoldsteinJA, PieperJA: Cytochrome P450 2C9 polymorphisms: a comprehensive review of the in vitro and human data.Pharmacogenetics12 (3) , 251–263 (2002).
   PubMedGoogle Scholar
• Zhao F , LokeC, RankinSC et al.: Novel CYP2C9 genetic variants in Asian subjects and their influence on maintenance warfarin dose.Clin. Pharmacol. Ther.76 , 210–219 (2004).
   PubMed Web of Science ®Google Scholar
• Limdi N , GoldsteinJ, BlaisdellJ et al.: Influence of CYP2C9 genotype on warfarin dose among African–American and European–Americans.Per. Med.4(2) , 157–169 (2007).
   PubMed Web of Science ®Google Scholar
• Scott SA , JaremkoM, LubitzSA et al.: CYP2C9*8 is prevalent among African–Americans: implications for pharmacogenetic dosing.Pharmacogenomics10(8) , 1243–1255 (2009).
   PubMed Web of Science ®Google Scholar
• Veenstra DL , YouJH, RiederMJ et al.: Association of vitamin K epoxide reductase complex 1 (VKORC1) variants with warfarin dose in a Hong Kong Chinese patient population.Pharmacogenet. Genomics.15(10) , 687–691 (2005).
   PubMed Web of Science ®Google Scholar
• Limdi NA , BeasleyTM, CrowleyMR et al.: VKORC1 polymorphisms, haplotypes and haplotype groups on warfarin dose among African–Americans and European–Americans.Pharmacogenomics9(10) , 1445–1458 (2008).
   PubMed Web of Science ®Google Scholar
• Ageno W , TurpieAG, SteidlL et al.: Comparison of a daily fixed 2.5-mg warfarin dose with a 5-mg, international normalized ratio adjusted, warfarin dose initially following heart valve replacement.Am. J. Cardiol.88 (1) , 40–44 (2001).
   PubMed Web of Science ®Google Scholar
• James AH , BrittRP, RaskinoCL, ThompsonSG: Factors affecting the maintenance dose of warfarin.J. Clin. Pathol.45(8) , 704–706 (1992).
   PubMed Web of Science ®Google Scholar
• Hirsh J , Guyatt,G, Albers,GW et al.: Executive summary: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition).Chest133(Suppl. 6) , 71 (2008).
   PubMed Web of Science ®Google Scholar
• Manotti C , MoiaM, PalaretiG et al.: Effect of computer-aided management on the quality of treatment in anticoagulated patients: a prospective, randomized, multicenter trial of APROAT.Haematologica86(10) , 1060–1070 (2001).
   PubMed Web of Science ®Google Scholar
• International Warfarin Pharmacogenetics Consortium: Estimation of the warfarin dose with clinical and pharmacogenetic data. N. Engl. J. Med.360 , 753–764. (2009)
   PubMed Web of Science ®Google Scholar
• Caraco Y , BlotnickS, MuszkatM: CYP2C9 genotype-guided warfarin prescribing enhances the efficacy and safety of anticoagulation: a prospective randomized controlled study.Clin. Pharmacol. Ther.83(3) , 460–470 (2008).
   PubMed Web of Science ®Google Scholar
• Anderson JL , HorneBD, StevensSM et al.: Randomized trial of genotype-guided versus standard warfarin dosing in patients initiating oral anticoagulation.Circulation116(22) , 2563–2570 (2007).
   PubMed Web of Science ®Google Scholar
• Hillman MA , WilkeRA, YaleSH et al.: A prospective, randomized pilot trial of model-based warfarin dose initiation using CYP2C9 genotype and clinical data.Clin. Med. Res.3(3) , 137–145 (2005).
   PubMedGoogle Scholar
• Eckman MH , RosandJ, GreenbergSM, GageBF: Cost–effectiveness of using pharmacogenetic information in warfarin dosing for patients with nonvalvular atrial fibrillation.Ann. Intern. Med.150(2) , 73–83 (2009).
   PubMed Web of Science ®Google Scholar
• You JH , TsuiKK, WongRS, ChengG: Potential clinical and economic outcomes of CYP2C9 and VKORC1 genotype-guided dosing in patients starting warfarin therapy.Clin. Pharmacol. Ther.86(5) , 540–547 (2009).
   PubMed Web of Science ®Google Scholar

▪ Websites

• Warfarin Dosing www.warfarindosing.org
   Google Scholar
• Genelex 2C9 DNA Drug Reaction Test http://store.genelex.com/index.php?main_page=product_info&cPath=1_2&products_id=18
   Google Scholar
• Trimgen eQ-PCRTM LC Warfarin Genotyping Kit www.trimgen.com/product_warfarin.asp
   Google Scholar
• US FDA: FDA Approves Updated Warfarin (Coumadin) Prescribing Information www.fda.gov/bbs/topics/NEWS/2007/NEW01684.html (Accessed on 15October2007)
   Google Scholar
• Table of Valid Genomic Biomarkers in the Context of Approved Drug Labels www.fda.gov/Drugs/ScienceResearch/ResearchAreas/Pharmacogenetics/ucm083378.htm
   Google Scholar